Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Inhalation Sciences AB (ISAB) yesterday presented previously announced positive data from the FDA-funded evaluation study of its advanced in vitro dissolution module, DissolvIt®, at the annual Drug Delivery to the Lungs (DDL) Conference in Edinburgh.
The results show that DissolvIt® generates pharmacokinetic (PK) data capable of predicting clinical plasma concentration profiles, demonstrating strong potential for its use in bioequivalence assessments of inhaled drugs.
"It's a breakthrough for Inhalation Sciences and a huge opportunity for companies looking to de-risk, accelerate timelines and comply with the latest regulatory recommendations", says Director of Projects, PhD Maria Malmlöf.
Furthermore, Dr. Per Gerde, presented the pharmacokinetic (PK) studies from the European research project "New Inhalation Formulations for Improved Delivery of Antimicrobials" (APRINHA). The data demonstrate that PreciseInhale® can distinguish between even subtle characteristics of different formulations and single out the most suitable candidates.
"Both these studies underscore the strength of our PreciseInhale® platform technology in bridging in vitro and in vivo understanding. These findings demonstrate how our approach can accelerate the development of inhaled therapies while significantly reducing the need for animals and active substance in early-stage research", says Dr. Per Gerde, Chief Scientific Officer at ISAB.
ISAB's presentations at DDL highlights the company's ongoing commitment to delivering innovative, science-driven technologies that enhance predictability and reproducibility in respiratory drug development.
About the APRINHA project
The APRINHA project is developing and evaluating five innovative formulations of the antibiotic apramycin, aiming to create an effective inhaled antibiotic treatment for lower respiratory tract infections (LRTIs), including those caused by antibiotic-resistant bacteria. ISAB was selected to conduct the pharmacokinetic studies in the APRINHA project due to the unique precision and capabilities of its proprietary PreciseInhale® platform technology. The APRINHA project is coordinated by the University of Zurich and brings together leading academic and industry partners across Europe.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.